Immuron Ltd IMRN
Immuron Ltd (Nasdaq: IMRN) is an infectious disease drug developer. Its lead program, Travelan (IMM-124E), is in Phase 2 for Prevention of travelers' diarrhea (ETEC).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Travelan (IMM-124E), oral polyclonal bovine antibody | Travelers' diarrhea prophylaxis (BLA path planned) | antibody | Phase 2 |
| IMM-529 | Clostridioides difficile infection / recurrent CDI | antibody | Pre-clinical |
| ProIBS (marketed in Australia as listed medicine/medical device) | IBS symptom relief | unclear | NA_NON_THERAPEUTIC |
Recent results and decisions
- Oct 28, 2026accepted FDA approved investigational new drug application for IMM-529, positioning it ready for Phase 2 clinical trials.
IMM-529 has an investigational new drug (IND) application approved by the U.S. FDA and is ready to go into Phase 2 clinical trials
Filing - Oct 28, 2026completed enrollment Immuron completed the Travelan n=851 clinical trial in FY26.
Travelan® n=851 trial completed
Filing - Oct 28, 2026completed enrollment Travelan® n=851 clinical trial has been completed, with IMM-124E now eligible for an end of Phase 2 meeting with the U.S. FDA.
IMM-124E is eligible for an end of Phase 2 meeting with the U.S. FDA (indication: traveler's diarrhea)
Filing
3 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 infectious disease companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.